Orchid Pharma Limited — Q4 FY25 earnings call

Call held 26 May 2025

Management summary

Orchid Pharma reported a 9% YoY sales growth to Rs. 237 crores and an EBITDA of Rs. 40 crores for Q4 FY25. Full-year FY25 sales grew 13% to Rs. 922 crores with an EBITDA of Rs. 156 crores. Key projects like 7-ACA faced delays, pushing commercialization to March 2027, while Enmetazobactam showed strong traction in India. The company anticipates a muted FY26 due to pricing pressures and CAPEX, but expects the merged Dhanuka Laboratories entity to provide a stronger platform with over Rs. 1,500 crore revenue.

Highlights

  • Q4 FY25 sales reached Rs. 237 crores, marking a 9% increase year-over-year.

  • EBITDA for Q4 FY25 stood at Rs. 40 crores.

  • Full-year FY25 sales grew 13% to Rs. 922 crores, up from Rs. 819 crores in FY24.

  • FY25 EBITDA was Rs. 156 crores, compared to Rs. 140 crores in FY24.

  • The AMS division incurred an operating drag of Rs. 9 crores in FY25 and is expected to remain EBITDA negative for approximately two more years.

  • The 7-ACA project's mechanical completion is delayed by 6 months to December 2026, with the first commercial product targeted for March 2027.

  • Enmetazobactam demonstrated strong early traction in India, achieving 10,000 patient treatments in half a year, which was the full-year estimate.

  • The merger with Dhanuka Laboratories has been cleared, projecting a combined entity revenue exceeding Rs. 1,500 crore and EBITDA of roughly Rs. 175 crore for FY26.

Concerns

  • 7-ACA Project Execution Delay

  • Enmetazobactam US Commercialization Impact from Allecra Insolvency

  • Continued Pricing Pressure and Muted FY26 Outlook

Key financials

  1. Revenue ₹237 Cr +9%YoY
  2. EBITDA ₹40 Cr
  3. Full Year Revenue ₹922 Cr +13%YoY
  4. Full Year EBITDA ₹156 Cr
  5. Full Year Volume Growth 19%

What they filed

Q1 FY27: revenue up 15.6%, net profit up 156.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue223 217 237 263 194 −13%207 −5%368 +55%304 +16%
EBITDA30 26 28 -6 -1 −105%2 −94%30 +8%14 +348%
Net profit27 21 22 -6 -6 −121%-13 −161%26 +16%3 +157%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Dhanuka Laboratories (FY25)
    ₹506 Cr Sales₹48 Cr EBITDA
  • Antimicrobial Solution (AMS) Division (FY25)
    ₹9 Cr EBITDA Drag

Guidance & targets

Profitability

  • AMS Division Profitability Profitability · in roughly 2 more years · Medium confidence profitable
    the division was EBITDA negative by about Rs. 9 crores and is likely to remain a drag for roughly 2 more years before turning profitable.

    — Manish Dhanuka, Managing Director

  • Merged Entity EBITDA Profitability · FY26 · Medium confidence roughly Rs. 175 crore
    and EBITDA of roughly Rs. 175 crore

    — Manish Dhanuka, Managing Director

Capacity

  • 7-ACA Project Mechanical Completion Capacity · December 2026 · Medium confidence December 2026
    We could be looking at the mechanical completion date of December 26, which is an increase of 6 months from our earlier estimates.

    — Manish Dhanuka, Managing Director

  • 7ACA Scale-up Capacity · before commercialization in Jammu · High confidence 1,000 liters

    Previously 10 liters → 1,000 liters

    we are scaling up there to the extent of 1,000 liters. So a hundred times scale up from where we are today before we commercialize in Jammu.

    — Manish Dhanuka, Managing Director

Product Launch

  • 7-ACA First Commercial Product Product Launch · March 2027 · Medium confidence March 2027
    The first commercial product is targeted for March 2027.

    — Manish Dhanuka, Managing Director

  • Cefiderocol First Validation Batches Product Launch · Q4 2026 · High confidence last quarter of 2026
    Development and project execution remain on schedule for this project with the first validation batches expected towards the last quarter of 2026.

    — Manish Dhanuka, Managing Director

  • Cefiderocol Commercial Launch Product Launch · Q2 2027 · High confidence second quarter of calendar year 2027
    Commercial launch will depend on regulatory approval in India, but it is expected to be in the second quarter of calendar year 2027.

    — Manish Dhanuka, Managing Director

Other

  • Dhanuka Merger Legal Process Completion Other · FY26 · High confidence within this Financial Year
    We aim to complete the legal process within this Financial Year and expect the combined business to generate a revenue in excess of Rs. 1,500 crore and EBITDA of roughly Rs. 175 crore offering investors a clearer, stronger platform from which to evaluate our progress.

    — Manish Dhanuka, Managing Director

Revenue

  • Merged Entity Revenue Revenue · FY26 · Medium confidence in excess of Rs. 1,500 crore
    expect the combined business to generate a revenue in excess of Rs. 1,500 crore

    — Manish Dhanuka, Managing Director

Margin

  • Margin Aspiration Margin · FY26 · High confidence mid-teen
    Nevertheless, our mid-teen margin aspiration remains intact, supported by volume growth, mixed optimization, and disciplined cost control.

    — Manish Dhanuka, Managing Director

Product Pipeline

  • ANDA Filings Product Pipeline · next 12 to 18 months · High confidence 2 to 3 differentiated cephalosporin ANDAs
    We also intend to file 2 to 3 differentiated cephalosporin ANDAs for the US market in the next 12 to 18 months, keeping Orchid at the forefront of complex anti-infectives for the coming future.

    — Manish Dhanuka, Managing Director

Volume

  • Volume Growth Volume · next year · Medium confidence mid-teens
    Yes, we have the capacity to deliver that. But like I said earlier, we don't want to be price leaders. So we will not strive for higher volume growth at the expense of our profit and pricing.

    — Mridul Dhanuka, Whole-time Director

Risks & concerns

  • 7-ACA Project Execution Delay

    high

    Mechanical completion of the 7-ACA project is delayed by 6 months to December 2026 due to site challenges.

    Management acknowledged

  • Enmetazobactam US Commercialization Impact from Allecra Insolvency

    high

    Electrotherapeutics' insolvency filing in Germany clouds near-term commercialization of Enmetazobactam in the US and other international markets.

    Management acknowledged

  • Continued Pricing Pressure and Muted FY26 Outlook

    high

    The company expects a muted FY26 due to ongoing pressure on demand and pricing, impacting overall numbers.

    Management acknowledged

  • AMS Division Operating Drag

    medium

    The Antimicrobial Solution (AMS) division was EBITDA negative by Rs. 9 crores in FY25 and is expected to remain a drag for roughly two more years.

    Management acknowledged

  • Surge in Receivables and Inventory

    medium

    A sudden surge in receivables and inventories tied up cash, attributed to sales in the last two months and higher inventory due to pricing pressure.

    Analyst acknowledged

  • Penicillin Price Compression

    medium

    Reduction in Pen-G prices is leading to price reduction, impacting products like Cefepime, with uncertainty on competitor reactions.

    Management acknowledged

  • Dependency on Customers for US Market Entry

    medium

    Historically, the company was exclusively dependent on a few customers for US market entry, but is now developing its own ANDAs and working with CMOs to mitigate this.

    Analyst acknowledged

Areas of evasion (2)

  • Allecra legal standing and options post-insolvency
  • Specific margin profile for Enmetazobactam in India

Q&A highlights

1 direct, 1 evasive
Allecra insolvency and royalty payments Evasive
Unfortunately, this is a public call, so I will not be able to share with you the options. Once we have them legally, we have to figure out our strategy. So it's a little too early because the announcement has just come.

Management was unable to provide clarity on the financial implications of Allecra's insolvency, including unreceived royalties and their standing as a creditor, indicating significant uncertainty.

Asked by Rupesh Tatiya

7-ACA project delay and government support Partial
we have been in constant communication with the government. We update them on quarterly basis what is the status of the project. And we also have an application with them to extend the date of the letter that they have provided us. And like I have alluded on the earlier calls, they have always given us comfort that, don't worry, we are there with you, but unfortunately, they have not given anything in writing.

The response highlights the government's verbal support for the delayed 7-ACA project but the lack of written commitment, posing a potential risk for the company's PLI scheme benefits.

Asked by Richa Chowdhary

Base business growth expectations Direct
No, Rupesh, I want to correct you. The base business will not continue to grow at 20% from here. That would include all the other things. So whatever the capacity utilizations CAPEX which was done in the past all of those have become operational, okay? ... You know, to fight more than that, we will have to compromise on margins which we don't intend to.

Management clarified that the base business growth will moderate from previous high rates, indicating a shift towards prioritizing margins over aggressive volume expansion in a competitive market.

Asked by Rupesh Tatiya

3 min read 7 chapters

Detailed narrative

Q4 FY25 Performance and Full Year Overview

Orchid Pharma reported Q4 FY25 sales of Rs. 237 crores, a 9% increase year-over-year, with an EBITDA of Rs. 40 crores. For the full fiscal year 2025, sales grew 13% to Rs. 922 crores, up from Rs. 819 crores in FY24, and EBITDA reached Rs. 156 crores, compared to Rs. 140 crores in the previous year. The company also achieved an 18-20% volume growth for FY25, despite absorbing a Rs. 6 crore one-time expense for GMP inspections in Q3.

Antimicrobial Solutions (AMS) Division Update

The AMS division, launched last year to cater to hospital sales, closed FY25 with a team of 70 members and engagements with over 500 physicians. However, it incurred an EBITDA negative drag of Rs. 9 crores for the year. Management anticipates the division will remain a drag for roughly two more years before achieving profitability, as it is still in its build-out phase and developing its sales and marketing model.

Key Project Timelines and Challenges

The 7-ACA project faces a 6-month delay, with mechanical completion now targeted for December 2026 and the first commercial product for March 2027. For Enmetazobactam, while India shows strong traction with 10,000 patients treated in half a year (matching the full-year estimate), US commercialization is clouded by Allecra's insolvency filing. The Cefiderocol project remains on schedule, with first validation batches expected in Q4 2026 and commercial launch in Q2 2027, pending regulatory approval in India.

Dhanuka Laboratories Merger and Combined Entity Outlook

The National Capital Law Tribunal (NCLT) has cleared the merger of Dhanuka Laboratories into Orchid Pharma, with the legal process expected to conclude within FY26. The combined entity is projected to generate revenue in excess of Rs. 1,500 crore and an EBITDA of roughly Rs. 175 crore for FY26. Dhanuka Laboratories contributed Rs. 506 crores in sales and Rs. 48 crores in EBITDA for FY25, providing a stronger platform for future growth.

FY26 Outlook and Strategic Focus

Orchid Pharma anticipates a muted FY26 due to continued pricing pressure and the ramp-up of CAPEX for the 7-ACA facility. Despite this, the company's mid-teen margin aspiration remains intact, supported by volume growth, mixed optimization, and disciplined cost control. The company also plans to file 2 to 3 differentiated cephalosporin ANDAs for the US market within the next 12 to 18 months, aiming to stay at the forefront of complex anti-infectives.

Raw Material Pricing and Inventory Management

The company experienced a sudden surge in receivables and inventories in Q4 FY25, tying up cash, primarily due to sales in the last two months and higher inventory built in anticipation of higher sales amidst pricing pressure. Management noted a reduction in Pen-G prices, impacting products like Cefepime, and is monitoring the market for stabilization. They aim to liquidate excess inventory over the next few months.

US Market Strategy and API Supply

Historically, Orchid Pharma was dependent on a few customers for US market entry for its raw materials. To mitigate this, the company is now developing its own ANDAs and exploring partnerships with CMOs for US FDA-approved sites. While direct API supply to the US market is not anticipated in the next two years, development work is ongoing, and two customers are currently registering Orchid's API products.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls